SCHEMBL2913492

SCHEMBL2913492

CN(C)c1ccc(CNC(=O)c2cn(CCCNc3ccc([N+](=O)[O-])c(N)n3)cc2-c2ccc(Cl)cc2Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 4/20 0.45
GSK3A P49840 3/20 0.45
CDK1 P06493 2/20 0.42
CCNB2 O95067 1/20 0.41
CCNB1 P14635 1/20 0.41
CCNB3 Q8WWL7 1/20 0.41
HPGD P15428 3/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C19 P33261 2/20 0.40
POLB P06746 1/20 0.38
MAPT P10636 2/20 0.36
MAPK1 P28482 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.34
HTT P42858 2/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2909753 0.91 HPGD (0.47) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2904255 0.90 GSK3B (0.47) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2941039 0.88 GSK3B (0.48) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2911606 0.86 GSK3B (0.48) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2909523 0.86 GSK3B (0.48) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2935625 0.86 GSK3B (0.45) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2903991 0.86 POLB (0.56) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2910272 0.86 GSK3B (0.45) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2912130 0.86 GSK3B (0.48) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL2910223 0.86 GSK3B (0.48) GSK3BGSK3ACDK1CCNB2CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537099-B1 PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 NOVARTIS VACCINES & DIAGNOSTIC (US) 2010-08-11 EP disclosed